ctDNA carries tumor-specific genetic mutations, providing real-time molecular insights into tumor characteristics [20,21,22,23], while CEA plays a crucial role in assessing therapeutic efficacy and monitoring recurrence risk [24,25,26]. Here, CEACAM5 is linked to neoplasm.